-
公开(公告)号:US09708253B2
公开(公告)日:2017-07-18
申请号:US15109733
申请日:2015-01-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Jingwu Duan , T. G. Murali Dhar , Bin Jiang , Ananta Karmakar , Arun Kumar Gupta , Zhonghui Lu , Carolyn A. Weigelt
IPC: C07C317/20 , C07C317/24 , C07C317/30 , C07D205/04 , C07D207/27 , C07D211/46 , C07D211/78 , C07D213/30 , C07D231/12 , C07D213/81 , C07D213/82 , C07D309/08 , C07D231/14 , C07D231/56 , C07D401/04 , C07D403/04 , C07D237/08 , C07D237/20 , C07D237/24 , C07D405/04 , C07D239/28 , C07C317/46 , C07D241/24 , C07D249/04 , C07D471/04 , C07D207/277 , C07D277/60 , C07D295/096 , C07D211/48 , C07D211/62 , C07D295/185 , C07D213/56 , C07D213/71 , C07D213/75 , C07D309/04 , C07D335/02 , C07D401/06 , C07D401/12 , C07D295/205 , C07D213/40 , C07D231/54 , C07D237/22 , C07D249/06 , C07D277/82 , C07D295/16 , C07D295/195
CPC classification number: C07C317/20 , C07C317/24 , C07C317/30 , C07C317/46 , C07C2601/02 , C07C2601/14 , C07D205/04 , C07D207/27 , C07D207/277 , C07D211/46 , C07D211/48 , C07D211/62 , C07D211/78 , C07D213/30 , C07D213/40 , C07D213/56 , C07D213/71 , C07D213/75 , C07D213/81 , C07D213/82 , C07D231/12 , C07D231/14 , C07D231/54 , C07D231/56 , C07D237/08 , C07D237/20 , C07D237/22 , C07D237/24 , C07D239/28 , C07D241/24 , C07D249/04 , C07D249/06 , C07D277/60 , C07D277/82 , C07D295/096 , C07D295/16 , C07D295/185 , C07D295/195 , C07D295/205 , C07D309/04 , C07D309/08 , C07D335/02 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D405/04 , C07D471/04
Abstract: Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.
-
公开(公告)号:US20160326115A1
公开(公告)日:2016-11-10
申请号:US15109727
申请日:2015-01-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Jingwu Duan , T.G. Murali Dhar , Bin Jiang , Ananta Karmakar , Arun Kumar Gupta , Zhonghui Lu
IPC: C07D211/54 , C07D211/96 , C07D405/06 , C07D309/08 , C07D401/06
CPC classification number: C07D211/54 , C07D211/96 , C07D309/08 , C07D401/06 , C07D405/06
Abstract: Described are RORγ modulators of the formula (I), [INSERT CHEMICAL STRUCTURE HERE] or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.
-
公开(公告)号:US11078186B2
公开(公告)日:2021-08-03
申请号:US16348195
申请日:2017-11-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Jingwu Duan , Bin Jiang , T. G. Murali Dhar , Zhonghui Lu , Arun Kumar Gupta , Ananta Karmakar
IPC: C07D401/14 , C07D207/06 , C07D207/12 , C07D207/16 , C07D401/06 , C07D403/04 , C07D405/12 , C07D413/06
Abstract: There are described RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.
-
公开(公告)号:US09771320B2
公开(公告)日:2017-09-26
申请号:US15109741
申请日:2015-01-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Jingwu Duan , T. G. Murali Dhar , Bin Jiang , Zhonghui Lu , Ananta Karmakar , Arun Kumar Gupta , Carolyn A. Weigelt
IPC: C07C317/14 , C07D213/81 , C07D401/04 , C07D237/08 , C07C317/20 , C07C317/30 , C07C317/46 , C07D471/04 , C07D213/30 , C07D213/56 , C07D309/04 , C07D309/14 , C07D317/44 , C07D231/12 , C07D239/38 , C07D241/12 , C07D471/10 , C07D257/04 , C07D261/08 , C07D263/32 , C07D271/06 , C07D211/36 , C07D295/16 , C07D295/20 , C07D303/06 , C07D305/14 , C07D205/04 , C07D211/62 , C07D213/40 , C07D213/75 , C07D295/155 , C07D295/108 , C07D319/20 , C07D285/06 , C07D295/18 , C07D295/22 , C07D303/34 , C07C317/22 , C07C317/44 , C07C317/32 , C07C317/50 , C07D213/85 , C07D295/185
CPC classification number: C07C317/14 , C07C317/20 , C07C317/22 , C07C317/30 , C07C317/32 , C07C317/44 , C07C317/46 , C07C317/50 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/10 , C07C2601/14 , C07C2601/16 , C07C2602/08 , C07D205/04 , C07D211/36 , C07D211/62 , C07D213/30 , C07D213/40 , C07D213/56 , C07D213/75 , C07D213/81 , C07D213/85 , C07D231/12 , C07D237/08 , C07D239/38 , C07D241/12 , C07D257/04 , C07D261/08 , C07D263/32 , C07D271/06 , C07D285/06 , C07D295/108 , C07D295/155 , C07D295/18 , C07D295/185 , C07D295/20 , C07D295/22 , C07D303/06 , C07D303/34 , C07D305/14 , C07D309/04 , C07D309/14 , C07D317/44 , C07D319/20 , C07D401/04 , C07D471/04 , C07D471/10
Abstract: Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.
-
公开(公告)号:US20200024257A1
公开(公告)日:2020-01-23
申请号:US16348195
申请日:2017-11-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Jingwu DUAN , Bin Jiang , T.G. Murali Dhar , Zhonghui LU , Arun Kumar Gupta , Ananta Karmakar
IPC: C07D401/14 , C07D207/16 , C07D207/06 , C07D207/12 , C07D401/06 , C07D403/04 , C07D413/06 , C07D405/12
Abstract: There are described RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.
-
公开(公告)号:US09637455B2
公开(公告)日:2017-05-02
申请号:US15109727
申请日:2015-01-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Jingwu Duan , T. G. Murali Dhar , Bin Jiang , Ananta Karmakar , Arun Kumar Gupta , Zhonghui Lu
IPC: C07D211/54 , C07D309/08 , C07D401/06 , C07D405/06 , C07D211/96 , A61K31/352 , A61K31/4418
CPC classification number: C07D211/54 , C07D211/96 , C07D309/08 , C07D401/06 , C07D405/06
Abstract: Described are RORγ modulators of the formula (I), [INSERT CHEMICAL STRUCTURE HERE] or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.
-
-
-
-
-